|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
01873 VIVA BIOTECH
Nominal 
2.590 -0.110 (-4.074%) | 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Turnover | 831,874 | -15.273% | 1,986,651 | 2,155,578 | 2,379,631 | 2,104,083 |
| Cost of Sales | (492,447) | -23.376% | (1,299,252) | (1,417,146) | (1,563,952) | (1,453,102) |
| Gross Profit | 339,427 | 0.083% | 687,399 | 738,432 | 815,679 | 650,981 |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | -- | |
| Change in FV & Impairment on Others | 52,997 | -11.287% | 78,106 | 154,515 | (363,539) | 181,738 | |
| Profit / (Loss) on Disposal | -- | -- | -- | -- | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | -- | -- | |
| Share of Results of Asso. & JCEs | (418) | -- | (95) | 0 | 0 | 0 | |
| Profit / (Loss) before Taxation | 171,695 | -7.450% | 295,705 | (55,953) | (459,165) | 347,701 | |
| Taxation | (23,058) | -44.141% | (73,718) | (43,837) | (45,055) | (47,141) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | -- | -- | -- | -- | |
| Non-controlling Interests | (26,832) | -2.177% | (54,693) | (16,323) | (24,255) | (13,014) | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | 121,805 | 4.278% | 167,294 | (116,113) | (528,475) | 287,546 | |
| 2025/06 - Interim RMB(K¥) | %Chg (Compare to Interim) | 2024/12 RMB(K¥) | 2023/12 RMB(K¥) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 9,085 | -59.344% | 33,353 | 149,207 | 163,068 | 156,533 |
| Depreciation & Amortisation | 107,446 | 5.753% | 210,884 | 208,389 | 178,301 | 150,851 |
| Directors' Emoluments | -- | -- | 8,577 | 9,655 | 10,420 | 9,187 |
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| Auditor's Opinion Status | N/A | -- | Unqualified | Unqualified | Unqualified (Modified Report) | Unqualified |
Market Valuation Indicators
| 2025/06 - Interim | %Chg (Compare to Interim) | 2024/12 | 2023/12 | 2022/12 | 2021/12 | |
| EPS (cts) | 6.000 | 20.000% | 8.000 | -6.000 | -28.000 | 15.000 |
| DPS (cts) | 0.000 | -- | 0.000 | 0.000 | 0.000 | 0.000 |
| Dividend Payout Ratio (%) | -- | -- | -- | -- | -- | -- |
| Cash flow per share ($) | -- | -- | 0.175 | 0.198 | 0.202 | 0.041 |
| NBV per share ($) | 1.829 | -- | 1.783 | 1.706 | 1.643 | 1.780 |
| Remarks: | Real time quote last updated: 11/09/2025 17:59 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (K¥) | RMB 121,805 |
| %Change | 4.278% |
| EPS / (LPS) | RMB 0.060 |
| NBV Per Share (¥) | RMB 1.829 |